undamentalytics Newsletter
Sign in

Bioage Labs, Inc. key statistics and ratios

In fiscal 2025, Bioage Labs, Inc. had return on equity of -27.1%, an operating margin of -1031.5%, debt equal to 1.0% of equity and a current ratio of 14.24. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Operating margin—<−999%<−999%
Net margin—−896.1%−912.3%
Free-cash-flow margin—−915.5%−850.7%
Return on equity−22.0%−27.1%−29.2%
Return on assets−19.8%−24.7%−27.3%
Asset turnover—0.030.03
Current ratio12.8614.2417.19
Debt to equity2.6%1.0%0.0%
Interest cover (operating income ÷ interest)n/mn/mn/m
R&D as % of revenue—822.3%847.8%
Capital spending as % of revenue—8.0%4.7%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $397m
Short-term assets $330mLonger-term assets $67m
What it owes, and who funded it · $397m
Short-term liabilities $19mLonger-term liabilities $3mShareholders' equity $375m
  • Short-term assets cover short-term liabilities $330m of assets due within a year against $19m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $330m short-term assets against $3m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$106m against $281,000 of interest.

From Bioage Labs, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BIOA vs RLAYBIOA vs CRBUBIOA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bioage Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioage Labs, Inc.